Product Code: PHA1243
The global Pharmaceutical Contract Manufacturing market was valued at US$146.0 billion in 2023 and is projected to grow at a CAGR of 10.3% during the forecast period 2023-2033.
“The Pharmaceutical Contract Manufacturing Market Report 2023-2033”: This report will prove invaluable to leading firms striving for new revenue pockets if they wish to better understand the industry and its underlying dynamics. It will be useful for companies that would like to expand into different industries or to expand their existing operations in a new region.
In regard to therapeutic performance and safety characteristics, generic medications are less expensive than their branded counterparts. One of the main factors fueling the demand for generics is the push to lower the rising healthcare expenses. The market entry of various less expensive generic substitutes was made possible by patent expiration. Some of the significant medications whose patents recently expired included Lucentis by Roche, Adasuve by Galen, Perforomist by Mylan, Northera by Lundbeck, and Narcan by Emergent BioSolutions.
Nuclear medicine contract manufacturing also encompasses the development and production of radiopharmaceuticals. Due to recent corporate acquisitions and share offers, interest in the radiopharmaceutical industry has increased. Also, in May 2021, Curium finalized the acquisition of IASON, which aided the firm in growing its service portfolio of life-saving diagnostic solutions and throughout the European market.
What Questions Should You Ask before Buying a Market Research Report?
- How is the pharmaceutical contract manufacturing market evolving?
- What is driving and restraining the pharmaceutical contract manufacturing market?
- How will each point of care diagnostic submarket segment grow over the forecast period and how much revenue will these submarkets account for in 2033?
- How will the market shares for each pharmaceutical contract manufacturing submarket develop from 2022 to 2033?
- What will be the main driver for the overall market from 2023 to 2033?
- Will leading pharmaceutical contract manufacturing markets broadly follow the macroeconomic dynamics, or will individual national markets outperform others?
- How will the market shares of the national markets change by 2033 and which geographical region will lead the market in 2033?
- Who are the leading players and what are their prospects over the forecast period?
- What are the pharmaceutical contract manufacturing projects for these leading companies?
- How will the industry evolve during the period between 2023 and 2033? What are the implications of pharmaceutical contract manufacturing projects taking place now and over the next 10 years?
- Is there a greater need for product commercialisation to further scale the pharmaceutical contract manufacturing market?
- Where is the pharmaceutical contract manufacturing market heading and how can you ensure you are at the forefront of the market?
- What are the best investment options for new product and service lines?
- What are the key prospects for moving companies into a new growth path and C-suite?
You need to discover how this will impact the pharmaceutical contract manufacturing market today, and over the next 10 years:
- Our 318-page report provides 143 tables, 184 charts/graphs exclusively to you
- The report highlights key lucrative areas in the industry so you can target them - NOW
- It contains in-depth analysis of global, regional and national sales and growth
- It highlights for you the key successful trends, changes and revenue projections made by your competitors.
This report tells you TODAY how the pharmaceutical contract manufacturing market will develop in the next 10 years, and in line with the variations in COVID-19 economic recession and bounce. This market is more critical now than at any point over the last 10 years.
Forecasts to 2033 and other analyses reveal commercial prospects
- In addition to revenue forecasting to 2033, our new study provides you with recent results, growth rates, and market shares
- You will find original analyses, with business outlooks and developments
- Discover qualitative analyses (including market dynamics, drivers, opportunities, restraints and challenges), cost structure, impact of rising pharmaceutical contract manufacturing prices and recent developments.
This report includes data analysis and invaluable insight into how COVID-19 will affect the industry and your company. Four COVID-19 recovery patterns and their impact, namely, ""V" ", "L", "W" and "U" are discussed in this report.
Segments Covered in the Report:
Services
- Pharmaceutical Manufacturing Services
- Pharmaceutical API Manufacturing Services
- Pharmaceutical FDF Manufacturing Services: Parenteral/Injectable Manufacturing Services, Tablet Manufacturing Services, Capsule Manufacturing Services, Oral Liquid Manufacturing Services, Semi-solid Manufacturing Services, Other Formulation Manufacturing Services
- Drug Development Services
- Lead Identification & Candidate Optimization
- Target Identification & Screening
- Target Validation & Functional Informatics
- Other Services
- Biologics Manufacturing Services
- Biologics API Manufacturing Services
- Biologics FDF Manufacturing Services
Drug Type
End User
- Big Pharmaceutical Companies
- Small & Medium-sized Pharmaceutical Companies
- Generic Pharmaceutical Companies
- Other End-users
In addition to the revenue predictions for the overall world market and segments, you will also find revenue forecasts for five regional and 18 leading national markets:
North America
Europe
- Germany
- UK
- France
- Italy
- Spain
- Switzerland
- Rest of Europe
Asia Pacific
- China
- Japan
- India
- Australia
- South Korea
- Rest of Asia Pacific
Latin America
- Brazil
- Mexico
- Rest of Latin America
MEA
- GCC
- South Africa
- Rest of MEA
The report also includes profiles and for some of the leading companies in the Pharmaceutical Contract Manufacturing Market, 2023 to 2033, with a focus on this segment of these companies' operations.
Leading companies and the potential for market growth:
- AbbVie Inc
- Abnova Corporation
- Aenova Group
- Almac Group
- Baxter
- Boehringer Ingelheim International
- Catalent Inc
- Charles River Laboratories
- Evonik Industries
- Fujifilm Holdings Corporation
- Grifols S.A
- Jubilant Pharmova Limited
|
- ICON Plc
- IQVIA
- Lonza
- Nipro Pharma Corporation
- Pfizer Inc
- Piramal Pharma Solutions
- Recipharm AB
- Samsung Biologics
- Siegfried Holding AG
- Thermo Fisher Scientific
- Vetter Pharma
- WuXi AppTec
|
Overall world revenue for pharmaceutical contract manufacturing market, 2023 to 2033 in terms of value the market will surpass US$145 billion in 2023, our work calculates. We predict strong revenue growth through to 2033. Our work identifies which organizations hold the greatest potential. Discover their capabilities, progress, and commercial prospects, helping you stay ahead.
How will the Pharmaceutical contract manufacturing Market, 2023 to 2033 report help you?
In summary, our 310+ page report provides you with the following knowledge:
- Revenue forecasts to 2033 for pharmaceutical contract manufacturing Market, 2023 to 2033 Market, with forecasts for service, drug type, end-users, each forecast at a global and regional level - discover the industry's prospects, finding the most lucrative places for investments and revenues.
- Revenue forecasts to 2033 for five regional and 21 key national markets - See forecasts for the pharmaceutical contract manufacturing Market, 2023 to 2033 market in North America, Europe, Asia-Pacific, Latin America, and MEA. Also forecasted is the market in the US, Canada, Mexico, Brazil, Germany, France, UK, Italy, Spain, Switzerland, China, India, Japan, Australia, South Korea, Brazil, GCC, and South Africa among other prominent economies.
- Prospects for established firms and those seeking to enter the market - including company profiles for 25 of the major companies involved in the pharmaceutical contract manufacturing Market, 2023 to 2033.
Find quantitative and qualitative analyses with independent predictions. Receive information that only our report contains, staying informed with invaluable business intelligence.
Information found nowhere else
With our new report, you are less likely to fall behind in knowledge or miss out on opportunities. See how our work could benefit your research, analyses, and decisions. Our study is for everybody needing commercial analyses for the pharmaceutical contract manufacturing Market, 2023 to 2033, market-leading companies. You will find data, trends and predictions.
Table of Contents
1 Report Overview
- 1.1 Objectives of the Study
- 1.2 Introduction to Pharmaceutical Contract Manufacturing Market
- 1.3 What This Report Delivers
- 1.4 Why You Should Read This Report
- 1.5 Key Questions Answered by This Analytical Report
- 1.6 Who is This Report for?
- 1.7 Methodology
- 1.7.1 Market Definitions
- 1.7.2 Market Evaluation & Forecasting Methodology
- 1.7.3 Data Validation
- 1.7.3.1 Primary Research
- 1.7.3.2 Secondary Research
- 1.8 Frequently Asked Questions (FAQs)
- 1.9 Associated Reports
- 1.10 About
2 Executive Summary
3 Market Overview
- 3.1 Key Findings
- 3.2 Market Dynamics
- 3.2.1 Market Driving Factors
- 3.2.1.1 Patent Expiry and Increasing Demand for Generic Drugs
- 3.2.1.2 Increasing Investments in Pharmaceutical R&D
- 3.2.1.3 Investments in Advanced Manufacturing Technologies by CDMOs
- 3.2.2 Market Restraining Factors
- 3.2.2.1 Introduction of Serialization
- 3.2.3 Market Opportunities
- 3.2.3.1 Increasing Demand for Biological Therapies
- 3.2.3.2 Growth in the Nuclear Medicine Sector
- 3.2.3.3 Growing Demand for Cell and Gene Therapies
- 3.3 COVID-19 Impact Analysis
- 3.4 Porter's Five Forces Analysis
- 3.4.1 Bargaining Power of Supplier
- 3.4.2 Bargaining Power of Buyer
- 3.4.3 Threat of New Entrants
- 3.4.4 Threat of Substitutes
- 3.4.5 Competitive Rivalry
- 3.5 PEST Analysis
- 3.6 SWOT Analysis
4 Pharmaceutical Contract Manufacturing Market, by Services, 2023-2033
- 4.1 Key Findings
- 4.2 Services Segment: Market Attractiveness Index
- 4.3 Pharmaceutical Contract Manufacturing Market Size Estimation and Forecast by Services
- 4.4 Pharmaceutical Manufacturing Services
- 4.4.1 Market Size by Region, 2023-2033 (US$ bn)
- 4.4.2 Market Share by Region, 2023 & 2033 (%)
- 4.4.3 Pharmaceutical API Manufacturing Services
- 4.4.3.1 Market Size by Region, 2023-2033 (US$ bn)
- 4.4.3.2 Market Share by Region, 2023 & 2033 (%)
- 4.4.4 Pharmaceutical FDF Manufacturing Services
- 4.4.4.1 Market Size by Region, 2023-2033 (US$ bn)
- 4.4.4.2 Market Share by Region, 2023 & 2033 (%)
- 4.4.4.3 Parenteral/Injectable Manufacturing Services
- 4.4.4.4 Tablet Manufacturing Services
- 4.4.4.5 Capsule Manufacturing Services
- 4.4.4.6 Oral Liquid Manufacturing Services
- 4.4.4.7 Semi-solid Manufacturing Services
- 4.4.4.8 Other Formulation Manufacturing Services
- 4.5 Drug Development Services
- 4.5.1 Market Size by Region, 2023-2033 (US$ bn)
- 4.5.2 Market Share by Region, 2023 & 2033 (%)
- 4.5.3 Lead Identification & Candidate Optimization
- 4.5.3.1 Market Size by Region, 2023-2033 (US$ bn)
- 4.5.3.2 Market Share by Region, 2023 & 2033 (%)
- 4.5.4 Target Identification & Screening
- 4.5.4.1 Market Size by Region, 2023 - 2033 (US$bn)
- 4.5.4.2 Market Share by Region, 2023 & 2033 (%)
- 4.5.5 Target Validation & Functional Informatics
- 4.5.5.1 Market Size by Region, 2023 - 2033 (US$bn)
- 4.5.5.2 Market Share by Region, 2023 & 2033 (%)
- 4.5.6 Other Services
- 4.5.6.1 Market Size by Region, 2023 - 2033 (US$bn)
- 4.5.6.2 Market Share by Region, 2023 & 2033 (%)
- 4.6 Biologics Manufacturing Services
- 4.6.1 Market Size by Region, 2023-2033 (US$ bn)
- 4.6.2 Market Share by Region, 2023 & 2033 (%)
- 4.6.3 Biologics API Manufacturing Services
- 4.6.3.1 Market Size by Region, 2023-2033 (US$ bn)
- 4.6.3.2 Market Share by Region, 2023 & 2033 (%)
- 4.6.4 Biologics FDF Manufacturing Services
- 4.6.4.1 Market Size by Region, 2023-2033 (US$ bn)
- 4.6.4.2 Market Share by Region, 2023 & 2033 (%)
5 Pharmaceutical Contract Manufacturing Market, by End-users, 2023-2033
- 5.1 Key Findings
- 5.2 End-users Segment: Market Attractiveness Index
- 5.3 Pharmaceutical Contract Manufacturing Market, by End-users
- 5.4 Big Pharmaceutical Companies
- 5.4.1 Market Size by Region, 2023-2033 (US$ bn)
- 5.4.2 Market Share by Region, 2023 & 2033 (%)
- 5.5 Small & Medium-Sized Pharmaceutical Companies
- 5.5.1 Market Size by Region, 2023-2033 (US$ bn)
- 5.5.2 Market Share by Region, 2023 & 2033 (%)
- 5.6 Generic Pharmaceutical Company
- 5.6.1 Market Size by Region, 2023-2033 (US$ bn)
- 5.6.2 Market Share by Region, 2023 & 2033 (%)
- 5.7 Other End-users
- 5.7.1 Market Size by Region, 2023-2033 (US$ bn)
- 5.7.2 Market Share by Region, 2023 & 2033 (%)
6 Pharmaceutical Contract Manufacturing Market, by Drug Type, 2023-2033
- 6.1 Key Findings
- 6.2 Drug Type Segment: Market Attractiveness Index
- 6.3 Pharmaceutical Contract Manufacturing Market Size Estimation and Forecast by Drug Type
- 6.4 Branded
- 6.4.1 Market Size by Region, 2023-2033 (US$ bn)
- 6.4.2 Market Share by Region, 2023 & 2033 (%)
- 6.5 Generic
- 6.5.1 Market Size by Region, 2023-2033 (US$ bn)
- 6.5.2 Market Share by Region, 2023 & 2033 (%)
7 Pharmaceutical Contract Manufacturing Market Analysis by Region, 2023-2033
- 7.1 Key Findings
- 7.2 Regional Market Size Estimation and Forecast
8 North America Pharmaceutical Contract Manufacturing Market, 2023-2033
- 8.1 Key Findings
- 8.2 North America Pharmaceutical Contract Manufacturing Market Attractiveness Index
- 8.3 North America Pharmaceutical Contract Manufacturing Market Forecast by Services
- 8.4 North America Pharmaceutical Contract Manufacturing Market Size Estimation and Forecast by End-users
- 8.5 North America Pharmaceutical Contract Manufacturing Market Size Estimation and Forecast by Drug Type
- 8.6 North America Pharmaceutical Contract Manufacturing Market Forecast by Country
- 8.7 U.S. Pharmaceutical Contract Manufacturing Market Analysis
- 8.8 Canada Pharmaceutical Contract Manufacturing Market Analysis
9 Europe Pharmaceutical Contract Manufacturing Market, 2023-2033
- 9.1 Key Findings
- 9.2 Europe Pharmaceutical Contract Manufacturing Market Attractiveness Index
- 9.3 Europe Pharmaceutical Contract Manufacturing Market Size Estimation and Forecast by Country
- 9.4 Europe Pharmaceutical Contract Manufacturing Market Size Estimation and Forecast by Services
- 9.5 Europe Pharmaceutical Contract Manufacturing Market Size Estimation and Forecast by End-users
- 9.6 Europe Pharmaceutical Contract Manufacturing Market Size Estimation and Forecast by Drug Type
- 9.7 Germany Pharmaceutical Contract Manufacturing Market Analysis
- 9.8 UK Pharmaceutical Contract Manufacturing Market Analysis
- 9.9 France Pharmaceutical Contract Manufacturing Market Analysis
- 9.10 Italy Pharmaceutical Contract Manufacturing Market Analysis
- 9.11 Spain Pharmaceutical Contract Manufacturing Market Analysis
- 9.12 Switzerland Pharmaceutical Contract Manufacturing Market Analysis
- 9.13 Rest of Europe Pharmaceutical Contract Manufacturing Market Analysis
10 Asia Pacific Pharmaceutical Contract Manufacturing Market Analysis
- 10.1 Key Findings
- 10.2 Asia Pacific Pharmaceutical Contract Manufacturing Market Attractiveness Index
- 10.3 Asia Pacific Pharmaceutical Contract Manufacturing Market Size Estimation and Forecast by Country
- 10.4 Asia Pacific Pharmaceutical Contract Manufacturing Market Size Estimation and Forecast by Services
- 10.5 Asia Pacific Pharmaceutical Contract Manufacturing Market Size Estimation and Forecast by End-users
- 10.6 Asia Pacific Pharmaceutical Contract Manufacturing Market Size Estimation and Forecast by Drug Type
- 10.7 Japan Pharmaceutical Contract Manufacturing Market Analysis
- 10.8 China Pharmaceutical Contract Manufacturing Market Analysis
- 10.9 India Pharmaceutical Contract Manufacturing Market Analysis
- 10.10 Australia Pharmaceutical Contract Manufacturing Market Analysis
- 10.11 South Korea Pharmaceutical Contract Manufacturing Market Analysis
- 10.12 Rest of Asia Pacific Pharmaceutical Contract Manufacturing Market Analysis
11 Latin America Pharmaceutical Contract Manufacturing Market Analysis
- 11.1 Key Findings
- 11.2 Latin America Pharmaceutical Contract Manufacturing Market Attractiveness Index
- 11.3 Latin America Pharmaceutical Contract Manufacturing Market Size Estimation and Forecast by Country
- 11.4 Latin America Pharmaceutical Contract Manufacturing Market Size Estimation and Forecast by Services
- 11.5 Latin America Pharmaceutical Contract Manufacturing Market Size Estimation and Forecast by End-users
- 11.6 Latin America Pharmaceutical Contract Manufacturing Market Size Estimation and Forecast by Drug Type
- 11.7 Brazil Pharmaceutical Contract Manufacturing Market Analysis
- 11.8 Mexico Pharmaceutical Contract Manufacturing Market Analysis
- 11.9 Rest of Latin America Pharmaceutical Contract Manufacturing Market Analysis
12 MEA Pharmaceutical Contract Manufacturing Market Analysis
- 12.1 Key Findings
- 12.2 MEA Pharmaceutical Contract Manufacturing Market Attractiveness Index
- 12.3 MEA Pharmaceutical Contract Manufacturing Market by Country, 2023, 2028 & 2033 (US$ bn)
- 12.4 MEA Pharmaceutical Contract Manufacturing Market Size Estimation and Forecast by Country
- 12.5 MEA Pharmaceutical Contract Manufacturing Market Size Estimation and Forecast by Services
- 12.6 MEA Pharmaceutical Contract Manufacturing Market Size Estimation and Forecast by End-users
- 12.7 MEA Pharmaceutical Contract Manufacturing Market Size Estimation and Forecast by Drug Type
- 12.8 GCC Pharmaceutical Contract Manufacturing Market Analysis
- 12.9 South Africa Pharmaceutical Contract Manufacturing Market Analysis
- 12.10 Rest of MEA Pharmaceutical Contract Manufacturing Market Analysis
13 Company Profiles
- 13.1 Competitive Landscape
- 13.2 Lonza
- 13.2.1 Company Snapshot
- 13.2.2 Company Overview
- 13.2.3 Financial Analysis
- 13.2.3.1 Net Revenue, 2018-2022
- 13.2.4 Service Benchmarking
- 13.2.5 Strategic Outlook
- 13.3 Catalent, Inc
- 13.3.1 Company Snapshot
- 13.3.2 Company Overview
- 13.3.3 Financial Analysis
- 13.3.3.1 Net Revenue, 2018-2022
- 13.3.3.2 Regional Market Shares, 2022
- 13.3.4 Service Benchmarking
- 13.3.5 Strategic Outlook
- 13.4 Recipharm AB
- 13.4.1 Company Snapshot
- 13.4.2 Company Overview
- 13.4.3 Financial Analysis
- 13.4.3.1 Net Revenue, 2017-2021
- 13.4.4 Service Benchmarking
- 13.4.5 Strategic Outlook
- 13.5 AbbVie Inc.
- 13.5.1 Company Snapshot
- 13.5.2 Company Overview
- 13.5.3 Financial Analysis
- 13.5.3.1 Net Revenue, 2018-2022
- 13.5.3.2 R&D, 2018-2022
- 13.5.3.3 Regional Market Shares, 2022
- 13.5.4 Service Benchmarking
- 13.5.5 Strategic Outlook
- 13.6 Thermo Fisher Scientific
- 13.6.1 Company Snapshot
- 13.6.2 Company Overview
- 13.6.3 Financial Analysis
- 13.6.3.1 Net Revenue, 2017-2021
- 13.6.3.2 R&D, 2017-2021
- 13.6.4 Service Benchmarking
- 13.6.5 Strategic Outlook
- 13.7 Siegfried Holding AG
- 13.7.1 Company Snapshot
- 13.7.2 Company Overview
- 13.7.3 Financial Analysis
- 13.7.3.1 Net Revenue, 2018-2022
- 13.7.3.2 R&D, 2018-2022
- 13.7.4 Service Benchmarking
- 13.7.5 Strategic Outlook
- 13.8 Evonik Industries
- 13.8.1 Company Snapshot
- 13.8.2 Company Overview
- 13.8.3 Financial Analysis
- 13.8.3.1 Net Revenue, 2018-2022
- 13.8.3.2 R&D, 2018-2022
- 13.8.3.3 Regional Market Shares, 2022
- 13.8.4 Service Benchmarking
- 13.8.5 Strategic Outlook
- 13.9 Boehringer Ingelheim International GmbH
- 13.9.1 Company Snapshot
- 13.9.2 Company Overview
- 13.9.3 Financial Analysis
- 13.9.3.1 Net Revenue, 2017-2021
- 13.9.3.2 R&D, 2017-2021
- 13.9.3.3 Regional Market Shares, 2021
- 13.9.4 Service Benchmarking
- 13.9.5 Strategic Outlook
- 13.10 Piramal Pharma Solutions
- 13.10.1 Company Snapshot
- 13.10.2 Company Overview
- 13.10.3 Service Benchmarking
- 13.10.4 Strategic Outlook
- 13.11 Samsung Biologics
- 13.11.1 Company Snapshot
- 13.11.2 Company Overview
- 13.11.3 Financial Analysis
- 13.11.3.1 Net Revenue, 2017-2021
- 13.11.3.2 Regional Market Shares, 2021
- 13.11.4 Service Benchmarking
- 13.11.5 Strategic Outlook
- 13.12 WuXi AppTec
- 13.12.1 Company Snapshot
- 13.12.2 Company Overview
- 13.12.3 Financial Analysis
- 13.12.3.1 Net Revenue, 2017-2021
- 13.12.4 Service Benchmarking
- 13.12.5 Strategic Outlook
- 13.13 FUJIFILM Holdings Corporation
- 13.13.1 Company Snapshot
- 13.13.2 Company Overview
- 13.13.3 Financial Analysis
- 13.13.3.1 Net Revenue, 2017-2021
- 13.13.3.2 R&D, 2017-2021
- 13.13.3.3 Regional Market Shares, 2021
- 13.13.4 Service Benchmarking
- 13.13.5 Strategic Outlook
- 13.14 ICON Plc
- 13.14.1 Company Snapshot
- 13.14.2 Company Overview
- 13.14.3 Financial Analysis
- 13.14.3.1 Net Revenue, 2018-2022
- 13.14.3.2 R&D, 2017-2021
- 13.14.3.3 Regional Market Shares, 2022
- 13.14.4 Service Benchmarking
- 13.14.5 Strategic Outlook
- 13.15 Abnova Corporation
- 13.15.1 Company Snapshot
- 13.15.2 Company Overview
- 13.15.3 Service Benchmarking
- 13.16 Vetter Pharma
- 13.16.1 Company Snapshot
- 13.16.2 Company Overview
- 13.16.3 Service Benchmarking
- 13.16.4 Strategic Outlook
- 13.17 Aenova Group
- 13.17.1 Company Snapshot
- 13.17.2 Company Overview
- 13.17.3 Financial Analysis
- 13.17.3.1 Net Revenue, 2017-2021
- 13.17.3.2 Regional Market Shares, 2021
- 13.17.4 Service Benchmarking
- 13.17.5 Strategic Outlook
- 13.18 Almac Group
- 13.18.1 Company Snapshot
- 13.18.2 Company Overview
- 13.18.3 Service Benchmarking
- 13.18.4 Strategic Outlook
- 13.19 Nipro Pharma Corporation
- 13.19.1 Company Snapshot
- 13.19.2 Company Overview
- 13.19.3 Financial Analysis
- 13.19.3.1 Net Revenue, 2018-2022
- 13.19.3.2 R&D, 2018-2022
- 13.19.3.3 Regional Market Shares, 2022
- 13.19.4 Service Benchmarking
- 13.19.5 Strategic Outlook
- 13.20 Jubilant Pharmova Limited
- 13.20.1 Company Snapshot
- 13.20.2 Company Overview
- 13.20.3 Financial Analysis
- 13.20.3.1 Net Revenue, 2018-2022
- 13.20.3.2 R&D, 2018-2022
- 13.20.3.3 Regional Market Shares, 2022
- 13.20.4 Service Benchmarking
- 13.20.5 Strategic Outlook
- 13.21 Grifols, S.A.
- 13.21.1 Company Snapshot
- 13.21.2 Company Overview
- 13.21.3 Financial Analysis
- 13.21.3.1 Net Revenue, 2018-2022
- 13.21.3.2 R&D, 2018-2022
- 13.21.3.3 Regional Market Shares, 2022
- 13.21.4 Service Benchmarking
- 13.21.5 Strategic Outlook
- 13.22 Pfizer Inc.
- 13.22.1 Company Snapshot
- 13.22.2 Company Overview
- 13.22.3 Financial Analysis
- 13.22.3.1 Net Revenue, 2018-2022
- 13.22.3.2 R&D, 2018-2022
- 13.22.3.3 Regional Market Shares, 2022
- 13.22.4 Service Benchmarking
- 13.22.5 Strategic Outlook
- 13.23 Charles River Laboratories
- 13.23.1 Company Snapshot
- 13.23.2 Company Overview
- 13.23.3 Financial Analysis
- 13.23.3.1 Net Revenue, 2017-2021
- 13.23.3.2 Regional Market Shares, 2021
- 13.23.4 Service Benchmarking
- 13.23.5 Strategic Outlook
- 13.24 IQVIA Inc.
- 13.24.1 Company Snapshot
- 13.24.2 Company Overview
- 13.24.3 Financial Analysis
- 13.24.3.1 Net Revenue, 2018-2022
- 13.24.3.2 R&D, 2018-2022
- 13.24.3.3 Regional Market Shares, 2022
- 13.24.4 Service Benchmarking
- 13.24.5 Strategic Outlook
- 13.25 Baxter
- 13.25.1 Company Snapshot
- 13.25.2 Company Overview
- 13.25.3 Financial Analysis
- 13.25.3.1 Net Revenue, 2018-2022
- 13.25.3.2 R&D, 2018-2022
- 13.25.3.3 Regional Market Shares, 2022
- 13.25.4 Service Benchmarking
14 Conclusion and Recommendations
- 14.1 Concluding Remarks from
- 14.2 Recommendations for Market Players